ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: ,2 Imatinib, a first-generation tyrosine kinase inhibitor (TKI), which targets the BCR-ABL fusion protein, has brought revolutionary change to therapy for chronic myelogenous leukemia.3